Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis

Journal of Affective Disorders

Volumn 266, Issue , 2020, Pages 540-548

  Li, Xinyuan ^a   Zhang, Congxiao ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Efficacy; Network meta analysis; Nine antidepressants; Post stroke depression

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

CHINESE; CLINICAL OUTCOME; DRUG EFFICACY; HAMILTON DEPRESSION RATING SCALE; HUMAN; META ANALYSIS; POST-STROKE DEPRESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; CEREBROVASCULAR ACCIDENT; CHINA; COMPLICATION; DEPRESSION; MAJOR DEPRESSION; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CHINA; CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; NETWORK META-ANALYSIS; SEROTONIN UPTAKE INHIBITORS; STROKE; TREATMENT OUTCOME;

EID: 85079055782     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2020.02.005     Document Type: Review

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, 1994, American Psychiatric Association, Washington, DC.
2. Anttila, S.A., Leinonen, E.V., A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 7 (2001), 249–264.
3. Behnke, K., Sogaard, J., Martin, S., Bauml, J., Ravindran, A.V., Agren, H., Vester-Blokland, E.D., Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J. Clin. Psychopharmacol. 23 (2003), 358–364.
4. Bramer, W.M., Reference checking for systematic reviews using Endnote. J. Med. Libr. Assoc. 106 (2018), 542–546.
5. Deng, L., Qiu, S., Yang, Y., Wang, L., Li, Y., Lin, J., Wei, Q., Yang, L., Wang, D., Liu, M., Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis. Oncotarget 9 (2018), 23718–23728.
6. Donegan, S., Williamson, P., D'Alessandro, U., Tudur-Smith, C., Assessing key assumptions of network meta-analysis: a review of methods. Res. Synth. Methods 4 (2013), 291–323.
7. Duan, X., Yao, G., Liu, Z., Cui, R., Yang, W., Mechanisms of transcranial magnetic stimulation treating on post-stroke depression. Front. Hum. Neurosci., 12, 2018, 215.
8. Egorova, N., Cumming, T., Shirbin, C., Veldsman, M., Werden, E., Brodtmann, A., Lower cognitive control network connectivity in stroke participants with depressive features. Transl. Psychiatry, 7, 2018, 4.
9. Hackett, M.L., Pickles, K., Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int. J. Stroke 9 (2014), 1017–1025.
10. He, J.R., Zhang, Y., Lu, W.J., Liang, H.B., Tu, X.Q., Ma, F.Y., Yang, G.Y., Zeng, L.L., Age-related frontal periventricular white matter hyperintensities and miR-92a-3p are associated with early-onset post-stroke depression. Front. Aging Neurosci., 9, 2017, 328.
11. Higgins, J.P., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L., Sterne, J.A., Cochrane bias methods group; cochranestatistical methods group. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
12. Leinonen, E., Skarstein, J., Behnke, K., Agren, H., Helsdingen, J.T., Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int. Clin. Psychopharmacol., 14, 1999, 228.
13. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lässig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
14. Levada, O.A., Troyan, A.S., Poststroke depression biomarkers: a narrative review. Front. Neurol., 9, 2018, 577.
15. Lökk, J., Delbari, A., Management of depression in elderly stroke patients. Neuropsychiatr. Dis. Treat. 6 (2010), 539–549.
16. Miranda, J.J., Moscoso, M.G., Toyama, M., Cavero, V., Diez-Canseco, F., Ovbiagele, B., Role of mHealth in overcoming the occurrence of post-stroke depression. Acta Neurol. Scand. 137 (2018), 12–19.
17. Nabavi, S.F., Turner, A., Dean, O., Sureda, A., Mohammad, S., Post-stroke depression therapy: where are we now?. Curr. Neurovasc. Res. 11 (2014), 279–289.
18. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
19. Niedermaier, N., Bohrer, E., Schulte, K., Schlattmann, P., Heuser, I., Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J. Clin. Psychiatry 65 (2004), 1619–1623.
20. Ng, I., Greenblatt, H.K., Greenblatt, D.J., Stereo-Psychopharmacology: the case of citalopram and escitalopram. Clin. Pharmacol. Drug Dev. 5 (2016), 331–335.
21. Qin, B., Chen, H., Gao, W., Zhao, L.B., Zhao, M.J., Qin, H.X., Chen, W., Chen, L., Yang, M.X., Efficacy, acceptability and tolerability of antidepressant treatments for patients with post-strokedepression: a network meta-analysis. Braz. J. Med. Biol. Res., 51, 2018, e7218.
22. Robinson, R.G., Spalletta, G., Poststroke depression: a review. Can. J. Psychiatry 55 (2010), 341–349.
23. Rouse, B., Chaimani, A., Li, T., Network meta-analysis: an introduction for clinicians. Intern. Emerg. Med. 12 (2017), 103–111.
24. Salanti, G., Ades, A.E., Ioannides, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64 (2011), 163–171.
25. Sanchez, C., Reines, E.H., Montgomery, S.A., A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?. Int. Clin. Psychopharmacol. 29 (2014), 185–196.
26. Schatzberg, A.F., Kremer, C., Rodrigues, H.E., Murphy, G.M., Jr The Mirtazapine vs. Paroxetine study group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am. J. Geriatr. Psychiatry 10 (2002), 541–550.
27. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The mini-international neuropsychiatric interview (m.i.n.i): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998), 22–33.
28. Statacorp, B., 2010. Stata statistical software. Release 5.
29. Sun, Y., Liang, Y., Jiao, Y., Lin, J., Qu, H., Xu, J., Zhao, C., Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ Open, 7, 2017, e016499.
30. Wang, E.Y., Meyer, C., Graham, G.D., Whooley, M.A., Evaluating screening tests for depression in post-stroke older adults. J. Geriatr. Psychiatry Neurol. 31 (2018), 129–135.
31. Watanabe, N., Omori, I.M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R., Furukawa, T.A., Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst. Rev., 7, 2011, CD006528.
32. Winstein, C.J., Stein, J., Arena, R., Bates, B., Cherney, L.R., Cramer, S.C., Deruyter, F., Eng, J.J., Fisher, B., Harvey, R.L., Lang, C.E., MacKay-Lyons, M., Ottenbacher, K.J., Pugh, S., Reeves, M.J., Richards, L.G., Stiers, W., Zorowitz, R.D., American Heart Association Stroke Council, council on cardiovascular and stroke nursing, council on clinical cardiology, and council on quality of care and outcomes research. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47 (2016), e98–e169.
33. Zhang, Y., Cheng, L., Chen, Y., Yang, G.Y., Liu, J., Zeng, L., Clinical predictor and circulating microRNA profile expression in patients with early onset post-stroke depression. J. Affect. Disord. 193 (2016), 51–58.
34. Zou, Y.Z., Cui, J.F., Han, B., Ma, A.L., Li, M.Y., Fan, H.Z., Chinese psychiatrists views on global features of CCMD-III, ICD-10 and DSM-IV. Asian J. Psychiatr. 1 (2008), 56–59.